RxDoctor Payments Data

Steven Havard, MD

Cardiovascular Disease · Mansfield, TXNPI 1669436325

Payments from drug & device makers

$42,953in general payments, 2019–2025

Across 203 payments — averaging $211.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$40K
  • Artivion, Inc.$595
  • Johnson & Johnson$394
  • Novartis$373
  • Tactile Systems Technology Inc$324
  • Medtronic$266
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$38,33689%
  • Travel & lodging$7872%
  • Food & beverage$3,8309%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,953 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$768,765
Medicare patients
848
Services billed
4,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban545$618,164
XareltoRivaroxaban393$429,971
Repatha SureclickEvolocumab169$151,620
EntrestoSacubitril/Valsartan99$128,406
BrilintaTicagrelor91$93,706
Repatha SyringeEvolocumab17$14,734
VascepaIcosapent Ethyl23$12,150
Ranolazine ErRanolazine90$10,601
Metoprolol Succinate797$10,378
Nebivolol Hcl141$10,072
Icosapent Ethyl23$9,519
Diltiazem 24hr Er (Cd)Diltiazem Hcl297$7,849
Prasugrel Hcl98$7,824
Isosorbide Mononitrate ErIsosorbide Mononitrate533$7,733
ClopidogrelClopidogrel Bisulfate475$5,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$618,164545 claims
Johnson & JohnsonXarelto$394$429,971393 claims
NovartisEntresto$373$128,40699 claims
AstraZenecaBrilinta$264$93,70691 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →